This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

13 Biotech Stocks Presenting New Clinical Data

BOSTON ( TheStreet) -- The American Society of Clinical Oncology (ASCO) annual meeting, held this year June 4-8, brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer.

The ASCO annual meeting also attracts investors in almost equal numbers because treating cancer is big business. Wall Street pays close attention because the ASCO meeting moves biotech and drug stocks, often well before the ASCO confab even gets started.

Toxic Supplements (Forbes)

I've assembled a list of biotech and drug stocks that will be presenting new clinical data at this year's ASCO meeting. The list isn't exhaustive, but covers stocks that will likely receive the most investor attention at the meeting. (And as I point out, many of these stocks have already started to run up as the ASCO meeting approaches.)

ASCO has already posted online the research abstract titles for this year's meeting. On May 20 at 6 p.m. EDT, ASCO will post the content of those abstracts, which will contain more information about the data to be presented.

1 of 14

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZIOP $13.28 2.80%
ARQL $2.32 0.00%
CLDX $17.83 -0.34%
CRIS $2.77 0.73%
NKTR $15.20 -2.80%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs